Use Case | Unlocking RWE about Immune Checkpoint Inhibitor Treatment in Diverse Cancer Types
Real-world evidence (RWE) is becoming a valuable addition to randomized controlled clinical trials (RCT) to better understand the mechanisms and outcomes of cancer treatments. However, most real-world data (RWD) is locked in a non-uniform patient reporting system by hospitals and healthcare professionals.
Download our use case in immuno-oncology by completing the form and discover how artificial intelligence can help unlock real-world evidence in immunotherapy.
Immune checkpoint inhibitors are indicated for a wide range of cancer types. To better understand the clinical performance and outcomes of these therapies, it is important to determine the distribution of indications for which a given treatment is prescribed. However, to answer what this distribution is in a real-life setting, there is a need to gain insights from unstructured data such as Electronic Health Records (EHRs)
The study aimed to gain granular insights into the use of immune checkpoint inhibitors in clinical practice:
- To identify and quantify the patient population treated with immune checkpoint inhibitors
- To quantify the patient population according to predefined indications for the selected immune checkpoint inhibitors
- To determine the patient population receiving the drug as first-line or second-line treatment
Immune checkpoint inhibitors are indicated for a wide range of cancer types. To better understand the clinical performance and outcomes of these therapies, it is important to determine the distribution of indications for which a given treatment is prescribed. However, to answer what this distribution is in a real-life setting, there is a need to gain insights from unstructured data such as Electronic Health Records (EHRs)
The study aimed to gain granular insights into the use of immune checkpoint inhibitors in clinical practice:
- To identify and quantify the patient population treated with immune checkpoint inhibitors
- To quantify the patient population according to predefined indications for the selected immune checkpoint inhibitors
- To determine the patient population receiving the drug as first-line or second-line treatment
